Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial

Eur Respir J. 2023 Oct 19;62(4):2300262. doi: 10.1183/13993003.00262-2023. Print 2023 Oct.

Abstract

Individuals with IPF who follow a MUFA diet report a lower incidence of pirfenidone gastrointestinal adverse events than those that follow a SFA diet, which could explain the different prevalence in GI pirfenidone AEs reported by countries in IPF cohorts https://bit.ly/3LuzAUJ

Trial registration: ClinicalTrials.gov NCT03539289.

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Diet
  • Humans
  • Idiopathic Pulmonary Fibrosis* / drug therapy
  • Pyridones* / adverse effects
  • Treatment Outcome
  • Vital Capacity

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • pirfenidone
  • Pyridones

Associated data

  • ClinicalTrials.gov/NCT03539289